This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
POU2F1 / POU domain, class 2, transcription factor 1 · IHC design guide
Design Immunohistochemistry for POU2F1
Plan POU2F1 chromogenic IHC in paraffin sections around the nuclear staining reported in most cells (HPA tissue IHC). This guide highlights high staining in colon endocrine cells (HPA tissue IHC), fixation consistency (standard IHC practice), and isoform considerations (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
POU2F1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining in most cells (HPA tissue IHC) | |
| Staining pattern | Nuclear in most cells; high in colon endocrine cells (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet M01766-1) | |
| Positive control | Colon+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Staining has medium consistency with RNA expression (HPA tissue IHC) | |
| Regulation | Ubiquitous expression (UniProt) | |
| Isoform / epitope | 6 isoforms; isoform 2 is lymphocyte-specific (UniProt) |
Section 1
Recommended POU2F1 IHC & IF Protocols
The catalog antibody uses EDTA pH 8.0 retrieval (datasheet M01766-1). The published IHC protocols below cover lung tumor, cardiac, and tumor tissue sections (PMC10183409; PMC13543148; PMC13097874).
| Sample | Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet M01766-1) |
| Fixation | Image fixative and duration unreported (datasheet M01766-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet M01766-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet M01766-1) |
| Primary antibody | Rabbit monoclonal (clone 19P20) anti-POU2F1, 1:50 recommended; image 2 μg/ml (datasheet M01766-1) |
| Primary incubation | Overnight at 4 °C (datasheet M01766-1) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet M01766-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | POU2F1-positive staining in endocrine cells of colon (HPA tissue IHC: High). HPA tissue profile: Nuclear expression in most cells. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet M01766-1); use each published protocol’s stated retrieval when reproducing that study (PMC13543148; PMC13097874).
Section 2
What Is the Expected POU2F1 Staining Pattern?
POU2F1 should stain nuclei in most cells, with prominent staining in selected endocrine, ductal, placental and germ cells (HPA: nuclear expression in most cells; tissue IHC). This agrees with its nuclear localisation and lack of a transmembrane segment (UniProt P14859: subcellular location and topology). Treat tissue IHC patterns as supported, with medium consistency between antibody staining and RNA expression (HPA: reliability Supported).
| Nuclear staining in colon or rectal endocrine cells, kidney collecting ducts, placental syncytiotrophoblast cell bodies, or testicular preleptotene spermatocytes. | These are reported high-staining cell populations and useful positive comparisons (HPA: tissue IHC, High). Score the named cells and their nuclei; staining elsewhere in the section does not replace that comparison (general IHC practice). |
| Predominantly cytoplasmic staining with little or no nuclear signal in a high-staining cell population. | This disagrees with the reported tissue IHC pattern (HPA: nuclear expression in most cells). Check morphology and controls before calling it POU2F1. Approved ER and vesicle localisation in ICC-IF does not establish the same pattern in paraffin IHC (HPA: subcellular ICC-IF). |
| Strong staining confined to a cell population reported as not detected, such as adipocytes or cardiomyocytes. | The result conflicts with those specific tissue observations (HPA: adipocytes and cardiomyocytes, Not detected). Consider antibody cross-reactivity or endogenous chromogen-generating activity, and compare with controls; neither cause follows from staining alone (general IHC practice). |
| Diffuse colour across tissue spaces or many cells without discernible nuclear boundaries. | This is difficult to score against the expected nuclear pattern (HPA: tissue IHC profile). Incomplete blocking, excess reagent, or detection background can produce diffuse staining (general IHC practice); assess a no-primary control and tissue morphology. |
| No nuclear staining in the named high-staining cells of a positive comparison section. | A negative test section is hard to interpret until the positive comparison works (HPA: tissue IHC, High). Review section quality and the IHC workflow, including retrieval and detection, without assuming a POU2F1-specific fixation effect (general IHC practice). |
💡Expected POU2F1 appearanceCall an IHC result positive when nuclei are clearly stained in the appropriate cells, especially the reported high-staining populations; dominant diffuse or exclusively cytoplasmic colour is suspect (HPA: tissue IHC, High; nuclear expression in most cells).
| Cell population and tissue | POU2F1 is described as ubiquitous, while HPA reports low tissue RNA specificity and different IHC staining levels among cell populations (UniProt P14859: tissue specificity; HPA: tissue IHC). Compare like cells when judging signal. |
| Isoform context | Six isoforms are listed, and isoform 2 is lymphocyte-specific (UniProt P14859: isoforms and tissue specificity). Those facts alone do not predict which isoform an antibody detects or require visible staining in every lymphocyte. |
| Assay-specific localisation | Nucleoplasm is the approved main ICC-IF location; ER and vesicles are additional approved locations (HPA: subcellular ICC-IF). For paraffin IHC, use the reported predominantly nuclear tissue pattern to interpret the slide (HPA: tissue IHC). |
| Strength of antibody evidence | HPA064323 and CAB002608 have Supported IHC status; HPA028256 and HPA058559 have no supplied IHC status (HPA: antibody validation). The supplied statuses do not establish performance for a different catalog antibody. |
| Chromogenic detection background | Endogenous activity can contribute colour independent of primary-antibody binding, depending on the detection chemistry (general IHC practice). A no-primary control helps identify that contribution; HPA tissue staining levels do not diagnose its cause. |
| Situation | Likely cause | Next action |
|---|---|---|
| The positive comparison lacks nuclear signal. | The run may have failed at retrieval, primary incubation, or detection; the slide alone cannot isolate the step (general IHC practice). | Check section integrity and reagent controls, then review the validated IHC-P workflow used for the run (general IHC practice). Use the named high-staining cells as the readout (HPA: tissue IHC, High). |
| Colour is predominantly cytoplasmic in paraffin IHC. | The pattern conflicts with nuclear expression reported in tissue IHC (HPA: tissue IHC profile); its cause is unresolved. | Inspect nuclear counterstain and morphology, then compare positive and no-primary sections (general IHC practice). Do not transfer ICC-IF ER or vesicle observations directly to paraffin IHC (HPA: subcellular ICC-IF). |
| A supposedly negative cell population stains strongly. | Cross-reactivity or chromogenic background is possible; HPA's Not detected call is an observation, not proof that every cell or preparation must be blank (HPA: tissue IHC; general IHC practice). | Identify the stained cell type, inspect the no-primary control, and compare with a named high-staining population on a comparable section (HPA: tissue IHC, High; general IHC practice). |
| Staining is diffuse and nuclear borders cannot be scored. | Nonspecific reagent binding or detection background may obscure compartment assignment (general IHC practice). | Review blocking, reagent concentrations, washing, and detection controls within the chosen IHC workflow (general IHC practice). Judge the result only when nuclear signal can be distinguished from background (HPA: tissue IHC profile). |
| Nuclear staining varies across the section. | Cell populations have different reported staining levels, including High, Medium, Low, and Not detected (HPA: tissue IHC). Uneven staining alone does not identify a technical failure. | Map staining to the named cell populations before comparing intensity. If the same population varies by section area, inspect section quality and processing consistency (HPA: tissue IHC; general IHC practice). |
| Q: IF/ICC shows signal outside the nucleus; is it inconsistent? | A: Nucleoplasm is the approved main location, with ER and vesicles approved as additional locations in ICC-IF (HPA: subcellular ICC-IF). | Interpret the IF/ICC image against those compartment assignments and its controls (HPA: subcellular ICC-IF; general IF practice). Use the separate IF/ICC guide for assay procedure. |
Experiment evidence
IHC & IF images showing POU2F1 staining
M01766-1 · IHCIHC analysis of OCT1/POU2F1 using anti-OCT1/POU2F1 antibody (M01766-1) . OCT1/POU2F1 was detected in a paraffin-embedded section of human br
M01766-1 · IHCIHC analysis of OCT1/POU2F1 using anti-OCT1/POU2F1 antibody (M01766-1) . OCT1/POU2F1 was detected in a paraffin-embedded section of human st
PB9317 · IHCAnti-Oct-1 vendor antibody, PB9317, IHC(P) IHC(P): Human Tonsil Tissue
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000143190-POU2F1/tissue/cerebral+cortex#imid_17775711
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000143190-POU2F1/tissue/colon#imid_17775621
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000143190-POU2F1/tissue/liver#imid_17775630
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000143190-POU2F1/tissue/kidney#imid_17775639
HPA · ICC-IF AF22Human Protein Atlas immunofluorescence, AF22, antibody HPA028256; green = POU2F1, blue = nucleus, red = microtubules.
HPA · ICC-IF AF22Human Protein Atlas immunofluorescence, AF22, antibody HPA028256; green = POU2F1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for POU2F1 IHC & IF
🧪Run colon first and assess its endocrine cells for POU2F1 staining (HPA: High in colon endocrine cells). Use adipose tissue adipocytes as the negative comparison (HPA: Not detected in adipocytes); on the colon slide, treat neighboring cells without nuclear signal as internal background references rather than presumed biological negatives (UniProt: ubiquitous expression; UniProt: nucleus).
Positive control tissue: Colon (Endocrine cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show POU2F1 in AF22, CACO-2, HAP1, A-431, U2OS, SH-SY5Y, with annotated localisation: Nucleoplasm (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control, a rabbit IgG control matched to the primary antibody’s clonality and isotype, and a POU2F1 knockout specimen processed in parallel (caption: rabbit primary; standard IHC controls). Quench endogenous peroxidase before HRP/DAB detection in colon sections (caption: HRP/DAB detection; standard IHC practice).
⚠️Feasibility: No supplied source reports a target-specific fixation window or fixation effect, and the selected-SKU paraffin-section caption leaves the fixative unreported (M01766-1 caption). That caption uses heat-mediated EDTA retrieval at pH 8.0, but it does not establish that retrieval is required or that frozen sections or IF are easier (M01766-1 caption). In colon, assess nuclear staining against any glandular background and endogenous peroxidase signal (UniProt: nucleus; standard IHC practice).
HPA tissue IHC evidence for POU2F1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Colon | Endocrine cells | High | Protein (IHC) | HPA → |
| Kidney | Collecting ducts | High | Protein (IHC) | HPA → |
| Placenta | Syncytiotrophoblasts - cell body | High | Protein (IHC) | HPA → |
| Rectum | Endocrine cells | High | Protein (IHC) | HPA → |
| Testis | Preleptotene spermatocytes | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Heart muscle | Cardiomyocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced POU2F1 IHC Tips
Troubleshoot POU2F1 staining by checking retrieval, nuclear localisation, cell identity and matched controls before comparing signal across sections.
How should I retrieve POU2F1 in paraffin sections when nuclear staining is weak?
Start with heat-mediated retrieval in EDTA at pH 8.0 (datasheet M01766-1). The selected paraffin-section image used this retrieval before overnight incubation at 4°C with 2 μg/ml primary antibody (caption M01766-1). If nuclei remain weak, vary heating duration on matched sections while holding antibody concentration, detection and development time constant (standard IHC practice). Compare nuclear signal with background and tissue preservation in every condition, since POU2F1 is nuclear and HPA reports nuclear expression in most cells (UniProt P14859 localisation; HPA tissue IHC).
Could fixation explain weak POU2F1 staining in my paraffin sections?
POU2F1-specific sensitivity to fixation is unknown from the supplied evidence; the selected paraffin-section caption does not state a fixative (caption M01766-1). Record the actual fixative, fixation duration, processing schedule and section age for each specimen before attributing weak staining to fixation (standard IHC practice). Compare sections processed together using the same EDTA retrieval at pH 8.0 and the same detection conditions (datasheet M01766-1; standard IHC practice). If signal differs, test a processing-matched positive control and inspect nuclear morphology, because damaged tissue and inconsistent processing can confound chromogenic scoring (standard IHC practice).
How should I assess cytoplasmic POU2F1 staining when the expected signal is nuclear?
Prioritise nuclear staining: UniProt assigns POU2F1 to the nucleus, while HPA describes nuclear expression in most tissue cells (UniProt P14859 localisation; HPA tissue IHC). HPA subcellular imaging places it mainly in the nucleoplasm and additionally reports endoplasmic reticulum and vesicles, so cytoplasmic signal alone needs careful corroboration (HPA subcellular). Review adjacent nuclei and cytoplasm separately at the same DAB development time, with a no-primary control for diffuse pigment (standard IHC practice). Its lack of a transmembrane segment provides no basis for treating crisp cell-border staining as the expected pattern (UniProt P14859 topology).
Could isoforms or modification explain discordant POU2F1 staining between samples?
POU2F1 has 6 listed isoforms, including a lymphocyte-specific isoform 2, so sample composition can affect interpretation (UniProt P14859 isoforms and tissue specificity). The supplied product evidence does not map the antibody epitope or establish which isoforms it recognises (caption M01766-1). POU2F1 also has reported phosphorylation sites, including residues 270, 276 and 283, but their effect on this antibody's tissue staining is unknown (UniProt P14859 modified residues). Before assigning a discordant pattern to an isoform or modification, compare matched processing and nuclear controls, then seek epitope-mapping evidence (standard IHC practice).
How can I check POU2F1 localisation with multiplex immunofluorescence?
Pair a POU2F1 channel with a marker identifying the cell population being assessed, and include a nuclear counterstain to test compartment assignment (standard IF practice; UniProt P14859 localisation). For example, assess the marker-positive population against the reported high signal in colon endocrine cells rather than assuming every neighbouring cell should match (HPA tissue IHC). Choose a fluorophore and filter set after inspecting an unstained section for autofluorescence, then use single-stain controls to assess channel bleed-through (standard IF practice). Permeabilise sufficiently for antibody access to the nuclear epitope, since POU2F1 is nuclear and has no transmembrane segment; optimise this separately for IF (UniProt P14859 localisation and topology; standard IF practice).
How can I separate nonspecific DAB deposit from POU2F1 nuclear signal?
The selected paraffin-section demonstration used 10% goat serum block, 2 μg/ml primary antibody and DAB detection (caption M01766-1). Begin troubleshooting with a no-primary control, then check whether background follows tissue edges, folds or areas of poor preservation (standard IHC practice). A peroxidase block and consistent DAB development help assess enzyme-related background; these are general chromogenic workflow measures, not POU2F1-specific validation (standard IHC practice). If background persists, titrate primary antibody below the demonstrated concentration on matched sections while checking that the expected nuclear signal remains detectable (caption M01766-1; UniProt P14859 localisation; standard IHC practice).
What scoring method captures POU2F1 staining without inflating results from uneven cellularity? ⚠ ANSWER MARKED FOR VERIFICATION
Score nuclear POU2F1 in a predefined cell population, recording the percentage of positive nuclei and, where intensity is reproducible, an H-score (UniProt P14859 localisation; standard IHC practice). Calculate H-score as 1 × weak plus 2 × moderate plus 3 × strong positive-cell percentages, giving a 0–300 range (standard IHC scoring practice). Normalise positive counts to the number of eligible nuclei, or report positive-cell density per mm² of viable tissue with the analysed area stated (standard IHC practice). Keep retrieval, imaging, DAB development and cell-selection rules consistent across specimens, and report compartment-specific results separately (standard IHC practice).
When should an apparent POU2F1-positive area be treated as artefact?
Look first for nuclear signal in intact, correctly identified cells: HPA reports nuclear expression in most cells, with high staining in kidney collecting ducts and colon endocrine cells (HPA tissue IHC). A strong membrane-only rim conflicts with POU2F1's nuclear assignment and lack of a transmembrane segment (UniProt P14859 localisation and topology). Exclude necrotic regions, folds and section edges from scoring, and compare suspicious DAB deposits with a no-primary control to assess endogenous enzyme or nonspecific development (standard IHC practice). Interpret absence cautiously, because HPA also records cell populations with undetected staining, including adipocytes in adipose tissue (HPA tissue IHC).
Boster reagents
Best POU2F1 / POU domain, class 2, transcription factor 1 IHC Antibodies
Two anti-POU2F1 antibodies have human tissue IHC images: breast cancer paraffin sections (M01766-1 image caption) and tonsil tissue (PB9317 image caption). Neither lists IF/ICC (catalog applications).
Real IHC data
Anti-Oct-1 Rabbit Monoclonal Antibody
Cat # M01766-1
Real IHC data
Anti-Oct-1/POU2F1 Antibody ®
Cat # PB9317
M01766-1 shows IHC in human breast cancer paraffin sections (M01766-1 image caption) and lists Human, Mouse and Rat reactivity (catalog). PB9317 shows IHC(P) in human tonsil tissue (PB9317 image caption) and lists Human reactivity (catalog).
Which to pick: For human paraffin-section IHC, M01766-1 has a breast cancer image with EDTA retrieval and DAB detection (M01766-1 image caption); PB9317 has a human tonsil IHC(P) image (PB9317 image caption). Choose M01766-1 when Mouse or Rat reactivity is needed, while recognizing that its shown IHC tissue is human (catalog reactivity; M01766-1 image caption). Neither SKU lists IF/ICC (catalog applications), and neither IHC caption reports the fixative (M01766-1 and PB9317 image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P14859 (PO2F1_HUMAN, POU domain, class 2, transcription factor 1).
- Human Protein Atlas. POU2F1 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. POU2F1 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the endoplasmic reticulum and vesicles..
- Human Protein Atlas. POU2F1 antibody validation summary (4 antibodies).
- Mechanistic insights into SOCS5-related DNA damage and cellular senescence in diabetic retinopathy. Cell death discovery 2026 — PMC13168495.
- High expression of transcription factor POU2F1 confers improved survival on smokers with lung adenocarcinoma: a retrospective study of two cohorts. Translational lung cancer research 2023 — PMC10183409.
- POU2F1 promotes hypertensive cardiac fibrosis by regulating mitochondrial homeostasis through PINK1/Parkin‑dependent mitophagy. Molecular medicine reports 2026 — PMC13543148.
- Isoimperatorin suppresses triple-negative breast cancer by modulating miR-874-3p/POU2F1 axis: a new avenue for metabolic and redox intervention. Biological research 2026 — PMC13097874.
- PubMed PMID:2905684 — UniProt-cited evidence.
- PubMed PMID:12663137 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for POU2F1 (POU domain, class 2, transcription factor 1). Expected localisation Nuclear staining in most cells (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet M01766-1). Validated IHC antibody: M01766-1 at 1:50 recommended; image 2 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Colon (Endocrine cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet M01766-1); 2. Fixation: Image fixative and duration unreported (datasheet M01766-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet M01766-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet M01766-1); 8. Primary antibody: Rabbit monoclonal (clone 19P20) anti-POU2F1, 1:50 recommended; image 2 μg/ml (datasheet M01766-1); 9. Primary incubation: Overnight at 4 °C (datasheet M01766-1). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Staining has medium consistency with RNA expression (HPA tissue IHC); Isoform / epitope: 6 isoforms; isoform 2 is lymphocyte-specific (UniProt); Regulation: Ubiquitous expression (UniProt). Evidence: UniProt P14859, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet M01766-1, PMC10183409, PMC13543148. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/POU2F1/immunohistochemistry-ihc-guide.